This announcement is a separate document:
康辰药业关于中药1.2类创新药金草片Ⅲ期临床试验达到主要研究终点的公告
Kangchen Pharmaceutical's announcement that the Phase III clinical trial of Jincao tablets, a Class 1.2 innovative traditional Chinese medicine, has reached the main research end
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.